Previous 10 | Next 10 |
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference PR Newswire CAMBRIDGE, Mass. , Jan. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...
Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 3, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeuti...
Short squeeze stocks are becoming a mainstay in the arsenal of trends to follow this year. Thanks to extensive breakouts from the likes of AMC Entertainment ( NYSE: AMC ), GameStop ( NYSE: GME ), and countless others, retail traders, in particular, are on the hunt for the next r...
Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month. One goal for both myself and readers is to cultivate the ability to rapidly identify highly asymmetric setups - LPTX fits that description after ESMO data in gastr...
3 Biotech Penny Stocks to Watch With the New Variant in Mind With another interesting day of trading penny stocks and blue chips off to a good start, it’s clear that volatility is here to stay. Although it may have seemed like things were calming down in the past few weeks, the e...
Longeveron LGVN +101% after Rare Pediatric Disease Designation for candidate Mammoth Energy Services TUSK +29% on EV charging contract Gracell Biotechnologies GRCL +26% on FDA Orphan Drug tag for GC012F BioHiTech Global BHTG +19% on Q3 results UWM Holdi...
Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 15, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and ...
Leap Therapeutics (NASDAQ:LPTX): Q3 GAAP EPS of -$0.92. Cash, cash equivalents and marketable debt securities totaling $78M Press Release For further details see: Leap Therapeutics reports Q3 results
Leap Therapeutics Reports Third Quarter 2021 Financial Results PR Newswire CAMBRIDGE, Mass. , Nov. 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics...
Looking to catch lightning in a bottle? Penny stocks can be your hot ticket. But in today’s article, we’re not talking about safety first, we’re talking about high-risk, volatile trading. One of the most frequently discussed topics this year is short squeeze stocks. ...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...